# Report for Rheumatologist: Sarah Miller

## Patient Summary
*   **Name:** Sarah Miller
*   **DOB:** 1962-03-15
*   **MRN:** MC-001001 (dashboard-item-1759853783245-patient-context)
*   **Primary Diagnosis:** Rheumatoid Arthritis (dashboard-item-1759853783245-patient-context)
*   **Other Active Problems:** Essential hypertension, Mild chronic kidney disease (dashboard-item-1759853783245-patient-context)
*   **Allergies:** Penicillin (rash) (dashboard-item-1759853783245-patient-context)

## 1. Patient History

*   **Rheumatoid Arthritis (RA):**
    *   Diagnosed in 2015 (dashboard-item-1759906300003-single-encounter-1).
    *   Initial presentation: Bilateral joint pain/swelling in hands/feet, morning stiffness >60 minutes, fatigue (dashboard-item-1759906300003-single-encounter-1, raw-bighand-dictation-hayes-2015).
    *   Initial treatment: Methotrexate (MTX) 10 mg weekly and Folic Acid 5 mg weekly (dashboard-item-1759906300003-single-encounter-1, raw-bighand-dictation-hayes-2015).
    *   MTX increased to 20 mg weekly in 2018 (dashboard-item-1759906076097-medication-timeline, raw-nervecentre-encounter-3).
    *   RA generally well-controlled on MTX until recently (dashboard-item-1759906300004-single-encounter-5).
*   **Essential Hypertension:**
    *   Diagnosed in 2018 (raw-nervecentre-encounter-3).
    *   Managed with Lisinopril 10 mg daily (dashboard-item-1759906076097-medication-timeline).
*   **Mild Chronic Kidney Disease (CKD):**
    *   Stable, noted in 2021 (dashboard-item-1759906300004-single-encounter-4).
*   **Colonoscopy:**
    *   Performed on 2023-11-10 for iron-deficiency anemia, revealed a 5 mm sessile polyp in the sigmoid colon (raw-medilogik-ems-colonoscopy).

## 2. Lab Results
*   **2015-08-10 (Initial RA diagnosis):**
    *   Elevated ESR (45 mm/hr) and CRP (25 mg/L) (raw-ice-lab-data-encounter-1).
    *   Positive Rheumatoid Factor (120 IU/mL) and Anti-CCP (>200 U/mL) (raw-ice-lab-data-encounter-1).
    *   Normal LFTs (ALT 25 U/L, AST 22 U/L, Alkaline Phosphatase 90 U/L, Total Bilirubin 0.7 mg/dL) (raw-ice-lab-data-encounter-1).
*   **2016-02-20 (Routine MTX monitoring):**
    *   Normal LFTs (ALT 30 U/L, AST 25 U/L, Alkaline Phosphatase 105 U/L, Total Bilirubin 0.8 mg/dL) (raw-ice-lab-data-encounter-2).
*   **2018-09-05 (MTX dose increase):**
    *   Normal LFTs (ALT 35 U/L, AST 30 U/L, Alkaline Phosphatase 110 U/L, Total Bilirubin 0.9 mg/dL) (raw-ice-lab-data-encounter-3).
*   **2025-06-15 (Sinusitis):**
    *   Creatinine slightly elevated (1.4 mg/dL), eGFR slightly decreased (58 mL/min/1.73m2) (raw-ice-lab-data-encounter-5).
    *   Normal LFTs (ALT 40 U/L, AST 35 U/L, Alkaline Phosphatase 120 U/L, Total Bilirubin 0.9 mg/dL) (raw-ice-lab-data-encounter-5).
*   **2025-06-21 (Acute Liver Injury):**
    *   Markedly elevated ALT (1650 U/L), AST (2100 U/L), Alkaline Phosphatase (350 U/L), Total Bilirubin (12.5 mg/dL), Direct Bilirubin (8.9 mg/dL) (raw-ice-lab-data-encounter-6).
    *   eGFR decreased (58 mL/min/1.73m2), Creatinine elevated (1.5 mg/dL) (raw-ice-lab-data-encounter-6).
    *   Platelets slightly decreased (165 x10^9/L) (raw-ice-lab-data-encounter-6).

## 3. Medication Timeline
*   **Methotrexate:** 10 mg weekly from 2015-08-10, increased to 20 mg weekly from 2018-09-05 (dashboard-item-1759906076097-medication-timeline).
*   **Folic Acid:** 5 mg weekly from 2015-08-10 (dashboard-item-1759906076097-medication-timeline).
*   **Lisinopril:** 10 mg daily from 2018-09-05 (dashboard-item-1759906076097-medication-timeline).
*   **Trimethoprim-Sulfamethoxazole:** 800/160 mg BID from 2025-06-15 to 2025-06-25 for acute bacterial sinusitis (dashboard-item-1759906076097-medication-timeline, raw-nervecentre-encounter-5).

## 4. Recent Event: Acute Liver Injury
*   **2025-06-21:** Presented to ED with severe fatigue, jaundice, epigastric pain, and confusion (raw-nervecentre-encounter-6).
*   Started Trimethoprim-Sulfamethoxazole 6 days prior (raw-nervecentre-encounter-6).
*   Physical exam: Jaundiced, drowsy, asterixis present (raw-nervecentre-encounter-6).
*   Impression: Acute liver injury likely DILI and/or severe methotrexate toxicity (raw-nervecentre-encounter-6).
*   IVC Ultrasound (2025-06-21): Minimally collapsible, suggests normal to increased intravascular volume (raw-viper-ultrasound-ivc).

## 5. Differential Diagnosis of Acute Liver Injury (per EASL guidelines)
*   **Primary Possibility:** Idiosyncratic DILI due to Trimethoprim-Sulfamethoxazole.
*   **Other Considerations:**
    *   Methotrexate-associated liver injury (DAFLD).
    *   Less likely: Lisinopril-induced DILI.
    *   Exclusion needed: Viral hepatitis, autoimmune hepatitis, ischemic hepatitis.
*   **EASL Guideline Reference:**  See conversation history with EASL web interface (iframe-item-easl-interface).

## 6. Actions Taken
*   Admitted to ICU (raw-nervecentre-encounter-6).
*   N-acetylcysteine started (raw-nervecentre-encounter-6).
*   GI/Hepatology and Hematology consulted (raw-nervecentre-encounter-6).

## 7. Recommendations
*   Given the potential for both MTX toxicity and DILI, recommend holding MTX until liver function normalizes (raw-nervecentre-encounter-6).
*   Since the patient has acute kidney injury, please adjust Lisinopril accordingly.
*   Follow up with GI/Hepatology regarding the need for liver biopsy to evaluate for chronic MTX changes.
*   Monitor Methotrexate levels as indicated.

## 8. Rheumatologist Contact Info
*To retrieve Rheumatologist contact info from an external directory, please provide access.*

## 9. Radiology Reports
*The following link simulates retrieval of the last 5 CT/MRI radiology reports related to the abdomen since 2015:*
`https://api.bedfordshirehospitals.nhs.uk/fhir-prd/r4/DiagnosticReport?patient=8a7f0d23-56c1-4f9a-9c42-8e7a3d6f1b12&category=http://loinc.org|LP29684-5&date=ge2015-01-01&modality=http://dicom.nema.org/resources/ontology/DCM|CT&modality=http://dicom.nema.org/resources/ontology/DCM|MRI&status=final&bodysite=http://snomed.info/sct|416949008&_sort=-date&_count=5`

## Audit Summary
*   Reviewed patient encounters and lab data from 2015-08-10 to 2025-06-21.
*   Medication timeline and problem list reviewed.
*   EASL guidelines consulted via web interface (iframe-item-easl-interface).
